-
Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data
. Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza: “We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s commitment to controlling the COVID-19 pandemic. “We are proud to support Moderna in the production of mRNA-1273. Our collaboration will allow for the manufacture of material equivalent to 400 million doses per year from Lonza’s facilities. Large-scale production began at our Portsmouth, US site at the end of September and we are on track to begin production at our Visp, Switzerland site before the end of the year. “With positive interim results from both Moderna’s and Pfizer’s mRNA…
-
Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux
Pierre-Alain Ruffieux today commences his role as Chief Executive Officer, following his appointment in June 2020. Albert M. Baehny resumes his role as Chairman of the Board of Directors, after a year in the role of Chief Executive Officer ad interim. Quote from Albert Baehny, Chairman of the Board of Directors, Lonza: “I would like to extend a warm welcome to Pierre-Alain as he joins the Lonza family. He brings with him more than two decades of industry experience and an outstanding track record of professional achievement in both scientific and manufacturing excellence. He combines this with deep industry knowledge and a clear strategic understanding of Lonza’s unique position in…
-
Investor Update Details Business Structure, Divisional Dynamics, New External Reporting and Guidance
Lonza provides the details of its new structural design, culture and external reporting 2023 Group guidance: double-digit sales growth, CORE EBITDA margin of around 33% – 35% and double-digit ROIC CAPEX in 2021 and 2022 is likely to remain at 2019 levels Biologics and Small Molecules are primary growth drivers, with contracted business up high double-digit versus 2019 and new projects in 2020 up >30% versus 2019 Updated financial reporting to include divisional KPIs for Sales, CORE EBITDA and CAPEX alongside existing Group metrics The Investor Update was hosted by Albert M. Baehny, Chairman and CEO ad interim, Lonza Group. He commented: “We have considered areas for review, now that…
-
Lonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement
Strong operational performance maintained during COVID-19; sites remained open and protection of employees continues to be a top priority Landmark ten-year collaboration with Moderna on the mRNA1 platform. The current focus is to manufacture an mRNA-based vaccine (mRNA-1273) for the novel coronavirus Group sales growth of 7.7%2 and resilient CORE EBITDA margin of 29.1% Growth driven by Pharma Biotech & Nutrition (LPBN) segment which delivered 10.8%2 sales growth and CORE EBITDA margin of 34.1% Specialty Ingredients (LSI) delivered flat sales growth alongside an increased CORE EBITDA margin of 19.7% LSI carve-out is nearing completion, with some activities left to undertake. In this context, Lonza has decided to divest the business through a…
-
Sven Abend Leaves Lonza to Take CEO Position in Germany
• Sven Abend has decided to resign from Lonza to take a CEO position in Germany. • Recruitment plans are under way to appoint a permanent replacement. • LSI is performing well and the segment carve-out process is nearing completion. Sven Abend has decided to resign from his position as a member of the Executive Committee of Lonza Group. He will relocate to Germany, where he has accepted the role of CEO. Sven joined Lonza Group in 2014 as Chief Strategy Officer. He has held the position of Chief Operating Officer and Head of Lonza Specialty Ingredients (LSI) since 2016. He will complete a full handover of his key responsibilities…
-
Lonza Appoints New Chief Executive Officer
The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020. Pierre-Alain is currently Head of Global Pharma Technical Operations at Roche where he and his 12,000-strong team are responsible for all aspects of pharmaceutical commercial manufacturing and supply chain operations, technical, quality assurance and regulatory. Prior to that he held roles of increasing seniority at Novartis and has over 20 years’ experience in biopharmaceuticals. Albert Baehny, Chairman of the Board said: “The Board is delighted to have appointed someone of Pierre-Alain’s calibre to be our next CEO. He brings deep knowledge of our industry, scientific excellence, customer focus and…
-
Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group
Dr Moncef Slaoui has decided to step down from his position as a member of the Lonza Group Board of Directors, following his appointment to the role of Chief Advisor for the U.S. government’s “Warp Speed” national vaccine program. Lonza Group wishes Dr Slaoui every success in his new role. Über Lonza Group Ltd. At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our…
